Diabetes, obesity & metabolism

GLP-1 Treatments in Type 1 Diabetes and Their Possible Effects on Heart, Kidney, and Safety

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Individuals with type 1 diabetes (T1D) have an increased risk for cardiovascular and renal complications.

  • Therapeutic strategies aimed at reducing cardiorenal risk in T1D are currently limited.
  • The efficacy of glucagon-like peptide-1 (GLP-1)-based therapies for T1D is not well established.
  • There is a need for further research to clarify the potential benefits of GLP-1 therapies in this population.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

May '26
GLP-1 Receptor Agonist Treatment and Heart and Kidney Outcomes in Type 1 Diabetes: A Matched Real-World Study
cited by 2 papers
journal article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Oct '25
Heart and kidney results of combining two diabetes drugs: GLP-1 receptor agonists and SGLT2 inhibitors
top 2% journal
cited by 5 papers
systematic review
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 191 papers
journal article
Jan '25
Kidney and heart health in chronic kidney disease patients taking GLP-1 receptor agonists
top 5% journal
cited by 58 papers
systematic review
Oct '21
Comparing diabetes drugs for people with heart disease: a network analysis of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
cited by 44 papers
systematic review
Mar '26
Kidney effects of GLP-1 receptor drugs and Tirzepatide in different stages of chronic kidney disease and metabolic types (type 2 diabetes and/or overweight)
top 20% journal
cited by 4 papers
systematic review
Aug '24
Heart, Kidney, and Safety Results of GLP-1 Drugs Alone and with SGLT2 Drugs in Type 2 Diabetes
top 1% journal
cited by 161 papers
systematic review
Aug '25
Comparing kidney and heart health outcomes of diabetes treatments in people with chronic kidney disease
cited by 3 papers
systematic review
Oct '25
How safe and effective combining two diabetes drugs (SGLT2 inhibitors and GLP-1 receptor agonists) is for people with type 2 diabetes
top 2% journal
cited by 27 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
5 days ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
1 week ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
2 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
3 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
4 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
6 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
7 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
8 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief